Breast
CAMBRIA-2
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Trial overview
Clinical Area
Medical Oncology
Disease / Condition
Breast cancer
Study Phase
III
Trial Identifiers
NCT05952557
GenesisCare Location(s)
Principal Investigator(s)